Sex steroids and the male skeleton: a tale of two hormones

Trends in Endocrinology and Metabolism

Volumn 21, Issue 2, 2010, Pages 89-95

  Callewaert, Filip ^a   Boonen, Steven ^a   Vanderschueren, Dirk ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; SEX HORMONE; SEX HORMONE BINDING GLOBULIN;

BONE GROWTH; BONE MASS; BONE MATURATION; BONE MINERAL; HOMEOSTASIS; HORMONAL REGULATION; HORMONE ACTION; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; MALE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; MODELS, BIOLOGICAL; SEX HORMONE-BINDING GLOBULIN; SKELETON;

EID: 75249094310     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.09.002     Document Type: Review

References (76)

1. Riggs B.L., et al. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23 (2002) 279-302
2. Khosla S., and Riggs B.L. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol. Metab. Clin. North Am. 34 (2005) 1015-1030
3. Vanderschueren D., et al. Androgens and bone. Endocr. Rev. 25 (2004) 389-425
4. Seeman E. Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J. Clin. Endocrinol. Metab. 86 (2001) 4576-4584
5. Khosla S., et al. Osteoporosis in men. Endocr. Rev. 29 (2008) 441-464
6. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 359 (2002) 1841-1850
7. Kaufman J.M., and Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26 (2005) 833-876
8. Khosla S., et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83 (1998) 2266-2274
9. Turner R.T., et al. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J. Orthop. Res. 8 (1990) 612-617
10. Vanderschueren D., et al. Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J. Bone Miner. Res. 8 (1993) 801-809
11. Venken K., et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J. Bone Miner. Res. 21 (2006) 576-585
12. Vandenput L., et al. Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J. Bone Miner. Res. 19 (2004) 1462-1470
13. Kawano H., et al. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9416-9421
14. Finkelstein J.S., et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med. 106 (1987) 354-361
15. Marcus R., et al. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 85 (2000) 1032-1037
16. Taes Y., et al. Estrogen-specific action on bone geometry and volumetric bone density: Longitudinal observations in an adult with complete androgen insensitivity. Bone 45 (2009) 392-397
17. Chiang C., et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J. Bone Miner. Res. 24 (2009) 621-631
18. Wiren K.M., et al. Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology 145 (2004) 3507-3522
19. Wiren K.M., et al. Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton. Bone 43 (2008) 440-451
20. Khosla S., et al. Clinical review 144: Estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 87 (2002) 1443-1450
21. Smith E.P., et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J. Clin. Endocrinol. Metab. 93 (2008) 3088-3096
22. Gennari L., et al. Aromatase activity and bone homeostasis in men. J. Clin. Endocrinol. Metab. 89 (2004) 5898-5907
23. Bouillon R., et al. Estrogens are essential for male pubertal periosteal bone expansion. J. Clin. Endocrinol. Metab. 89 (2004) 6025-6029
24. Lanfranco F., et al. A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. Bone 43 (2008) 628-635
25. Rochira V., et al. Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone. Bone 40 (2007) 1662-1668
26. Vanderschueren D., et al. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 138 (1997) 2301-2307
27. Vidal O., et al. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5474-5479
28. Sims N.A., et al. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J. Clin. Invest. 111 (2003) 1319-1327
29. Moverare S., et al. Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13573-13578
30. Callewaert F., et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J. 23 (2009) 232-240
31. Lapauw B.M., et al. Serum estradiol is associated with volumetric BMD and modulates the impact of physical activity on bone size at the age of peak bone mass: a study in healthy male siblings. J. Bone Miner. Res. 24 (2009) 1075-1085
32. Ophoff J., et al. Sex steroids during bone growth: a comparative study between mouse models for hypogonadal and senile osteoporosis. Osteoporos. Int. 20 (2009) 1749-1757
33. Sjogren K., et al. Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects. J. Bone Miner. Res. 24 (2009) 1263-1270
34. Windahl S.H., et al. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J. Clin. Invest. 104 (1999) 895-901
35. Lindberg M.K., et al. Estrogen receptor specificity in the regulation of the skeleton in female mice. J. Endocrinol. 171 (2001) 229-236
36. Vandenput L., et al. Testosterone prevents orchidectomy-induced bone loss in estrogen receptor-alpha knockout mice. Biochem. Biophys. Res. Commun. 285 (2001) 70-76
37. Juul A. The effects of oestrogens on linear bone growth. Hum. Reprod. Update 7 (2001) 303-313
38. Lupu F., et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229 (2001) 141-162
39. Venken K., et al. Growth without Growth Hormone Receptor: Estradiol Is a Major Growth Hormone-Independent Regulator of Hepatic Insulin-Like Growth Factor-I Synthesis. J. Bone Miner. Res. 20 (2005) 2138-2149
40. Lee K., et al. Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature 424 (2003) 389
41. Callewaert F., et al. Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice. J. Bone Miner. Res. 23 (2008) S40
42. Reim N.S., et al. Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J. Bone Miner. Res. 23 (2008) 694-704
43. Vandenput L., et al. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J. Bone Miner. Res. 17 (2002) 2080-2086
44. Araujo A.B., et al. Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J. Clin. Endocrinol. Metab. 93 (2008) 2135-2141
45. Khosla S., et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86 (2001) 3555-3561
46. Center J.R., et al. Hormonal and biochemical parameters and osteoporotic fractures in elderly men. J. Bone Miner. Res. 15 (2000) 1405-1411
47. van den Beld A.W., et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J. Clin. Endocrinol. Metab. 85 (2000) 3276-3282
48. Khosla S., et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J. Bone Miner. Res. 20 (2005) 730-740
49. Mellstrom D., et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J. Bone Miner. Res. 21 (2006) 529-535
50. Amin S., et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am. J. Med. 119 (2006) 426-433
51. Meier C., et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch. Intern. Med. 168 (2008) 47-54
52. Bjornerem A., et al. A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromso Study. Eur. J. Endocrinol. 157 (2007) 119-125
53. Goderie-Plomp H.W., et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J. Clin. Endocrinol. Metab. 89 (2004) 3261-3269
54. Mellstrom D., et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J. Bone Miner. Res. 23 (2008) 1552-1560
55. Szulc P., et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J. Clin. Endocrinol. Metab. 86 (2001) 192-199
56. Gennari L., et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J. Clin. Endocrinol. Metab. 88 (2003) 5327-5333
57. Khosla S. Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. Bone 43 (2008) 414-417
58. Gennari L., et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J. Clin. Endocrinol. Metab. 89 (2004) 2803-2810
59. Lorentzon M., et al. Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J. Bone Miner. Res. 21 (2006) 332-339
60. Eriksson A.L., et al. Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J. Clin. Endocrinol. Metab. 94 (2009) 1033-1041
61. Huhtaniemi I.T., et al. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J. Clin. Endocrinol. Metab. 94 (2009) 277-284
62. Leder B.Z., and Finkelstein J.S. Gonadal steroids and the skeleton in men. Clinical aspects. In: Orwoll E.S., and Bliziotes M. (Eds). Osteoporosis - Pathophysiology and Clinical Management (2002), Humana Press 393-411
63. Behre H.M., et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82 (1997) 2386-2390
64. Katznelson L., et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 81 (1996) 4358-4365
65. Snyder P.J., et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84 (1999) 1966-1972
66. Fink H.A., et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J. Clin. Endocrinol. Metab. 91 (2006) 3908-3915
67. Kenny A.M., et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. 56 (2001) M266-272
68. Snyder P.J., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 84 (1999) 2647-2653
69. Orwoll E., et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch. Intern. Med. 166 (2006) 2124-2131
70. Ophoff J., et al. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 150 (2009) 3558-3566
71. Orwoll E., et al. Testosterone and estradiol among older men. J. Clin. Endocrinol. Metab. 91 (2006) 1336-1344
72. Legrand E., et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone 29 (2001) 90-95
73. Martinez Diaz-Guerra G., et al. Hormonal and anthropometric predictors of bone mass in healthy elderly men: major effect of sex hormone binding globulin, parathyroid hormone and body weight. Osteoporos. Int. 12 (2001) 178-184
74. Eriksson A.L., et al. SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J. Clin. Endocrinol. Metab. 91 (2006) 5029-5037
75. Leblanc E.S., et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J. Clin. Endocrinol. Metab. 94 (2009) 3337-3346
76. de Ronde W., et al. Associations of sex-hormone-binding globulin (SHBG) with non-SHBG-bound levels of testosterone and estradiol in independently living men. J. Clin. Endocrinol. Metab. 90 (2005) 157-162